CH636269A5 - Process for the concentration of hepatitis B antigen and process for its purification - Google Patents
Process for the concentration of hepatitis B antigen and process for its purification Download PDFInfo
- Publication number
- CH636269A5 CH636269A5 CH310877A CH310877A CH636269A5 CH 636269 A5 CH636269 A5 CH 636269A5 CH 310877 A CH310877 A CH 310877A CH 310877 A CH310877 A CH 310877A CH 636269 A5 CH636269 A5 CH 636269A5
- Authority
- CH
- Switzerland
- Prior art keywords
- hbsag
- gradient
- rotor
- plasma
- salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 208000002672 hepatitis B Diseases 0.000 title claims description 21
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 title claims description 13
- 238000000746 purification Methods 0.000 title claims description 7
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 72
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 238000005199 ultracentrifugation Methods 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 6
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 239000008363 phosphate buffer Substances 0.000 description 9
- 238000011068 loading method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- PXKSAXUKRMRORY-ZWKOTPCHSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2r)-2-(2,5-dihydropyrrol-1-yl)cyclohexyl]-n-methylacetamide Chemical compound N1([C@@H]2CCCC[C@@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CC=CC1 PXKSAXUKRMRORY-ZWKOTPCHSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- -1 cesium ions Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Centrifugal Separators (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7657/77A GB1554811A (en) | 1977-02-23 | 1977-02-23 | Purifying hepatitis b surface antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH636269A5 true CH636269A5 (en) | 1983-05-31 |
Family
ID=9837320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH310877A CH636269A5 (en) | 1977-02-23 | 1977-03-11 | Process for the concentration of hepatitis B antigen and process for its purification |
Country Status (6)
| Country | Link |
|---|---|
| JP (2) | JPS53115812A (enrdf_load_stackoverflow) |
| CA (1) | CA1088426A (enrdf_load_stackoverflow) |
| CH (1) | CH636269A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2709581A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2382238A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1554811A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7711378A (nl) * | 1976-11-02 | 1978-05-05 | Merck & Co Inc | Werkwijze voor het bereiden van preparaten die dane-deeltjes bevatten. |
| FR2470795A1 (fr) * | 1979-12-07 | 1981-06-12 | Pasteur Institut | Procede de purification de particules d'origine biologique, notamment de l'antigene de surface du virus de l'hepatite b (aghbs) et les produits obtenus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3636191A (en) * | 1969-10-08 | 1972-01-18 | Cancer Res Inst | Vaccine against viral hepatitis and process |
| US4029764A (en) * | 1974-12-09 | 1977-06-14 | Merck & Co., Inc. | Hepatitis A antigen |
| US4017360A (en) * | 1975-05-14 | 1977-04-12 | Merck & Co., Inc. | Method for purifying hepatitis B antigen |
-
1977
- 1977-02-23 GB GB7657/77A patent/GB1554811A/en not_active Expired
- 1977-03-01 CA CA272,890A patent/CA1088426A/en not_active Expired
- 1977-03-02 FR FR7706090A patent/FR2382238A1/fr active Granted
- 1977-03-04 DE DE19772709581 patent/DE2709581A1/de active Granted
- 1977-03-11 CH CH310877A patent/CH636269A5/de not_active IP Right Cessation
- 1977-03-19 JP JP2981477A patent/JPS53115812A/ja active Granted
-
1983
- 1983-01-27 JP JP58010648A patent/JPS58180431A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6313969B2 (enrdf_load_stackoverflow) | 1988-03-29 |
| JPS53115812A (en) | 1978-10-09 |
| FR2382238B1 (enrdf_load_stackoverflow) | 1981-05-29 |
| CA1088426A (en) | 1980-10-28 |
| GB1554811A (en) | 1979-10-31 |
| DE2709581A1 (de) | 1978-09-07 |
| DE2709581C2 (enrdf_load_stackoverflow) | 1988-04-07 |
| FR2382238A1 (fr) | 1978-09-29 |
| JPS58180431A (ja) | 1983-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2711773A1 (de) | Verfahren zur reinigung und isolierung von hepatitisvirus zur herstellung eines impfstoffes | |
| DE2816864C2 (de) | Verfahren zur Herstellung von Hepatitis B-Kern-Antigen | |
| CH629668A5 (de) | Verfahren zum reinigen von hepatitis-b-antigen. | |
| DE68912115T2 (de) | Ausscheidungsverfahren für die herstellung von thromboplastinreagenzien. | |
| DE2243572A1 (de) | Verfahren zur gewinnung von antigenem material | |
| DE2833545A1 (de) | Hochmolekulare meningokokken- gruppe c-vaccine und verfahren zu ihrer herstellung | |
| DE2555169C2 (enrdf_load_stackoverflow) | ||
| DE3152621C2 (enrdf_load_stackoverflow) | ||
| DE2734150A1 (de) | Verfahren zur gewinnung von human- lysozym | |
| CH636269A5 (en) | Process for the concentration of hepatitis B antigen and process for its purification | |
| DE2617870C2 (enrdf_load_stackoverflow) | ||
| DE2707913C2 (de) | Verfahren zum Nachweis von rheumatoiden Faktoren | |
| DE2950004C2 (de) | Verfahren zur Herstellung von Frühsommer-Meningoenzephalitis-Virus(FSME-Virus)-Vakzinen | |
| DE3424640A1 (de) | Verfahren zur gewinnung und/oder bestimmung von humanspezifischem interferon im blut | |
| DE2748520C2 (enrdf_load_stackoverflow) | ||
| DE1907014A1 (de) | Verfahren zur Trennung von Blutkomponenten,insbesondere von immunologisch aktiven Globulinen,von anderen Komponenten | |
| DE2428955C3 (de) | Verfahren zur Abtrennung der enzymatischen Komponente mit in vivo antikoagulierender und in vitro koagulierender Wirkung aus dem Gift der Schlange Ancistrodon rhodostoma und daraus hergestellte Mittel | |
| DE60118409T2 (de) | Herstellungsverfahren von immunglobulinen, die gegen menschliche thymozyten gerichtet sind | |
| DE2353035B2 (de) | Verfahren zur Stabilisierung menschlicher oder tierischer Körperflüssigkeiten oder pflanzlicher Extrakte | |
| DE3913438A1 (de) | Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension | |
| DE2243237A1 (de) | Nachweis der immunreaktion gegenueber krebs | |
| DE248984C (enrdf_load_stackoverflow) | ||
| CH617350A5 (en) | Process for the preparation of HB-Ag vaccines with high-level antibody formation | |
| DE949252C (de) | Verfahren zur Isolierung von Antitoxinen und verwandten Eiweisskoerpern | |
| DE3150935A1 (de) | Verfahren zur herstellung eines hepatitis-b impfstoffes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |